Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000
Debt
Debt-to-Equity Ratio1.52
Current Ratio1.72
Quick Ratio1.48
Price-To-Earnings
Trailing P/E Ratio24.32
Forward P/E Ratio21.93
P/E Growth1.64
Sales & Book Value
Annual Sales$1.86 billion
Price / Sales3.33
Cash Flow$8.1094 per share
Price / Cash15.90
Book Value$22.11 per share
Price / Book5.83
Profitability
EPS (Most Recent Fiscal Year)$5.27
Net Income$123.35 million
Net Margins6.38%
Return on Equity25.26%
Return on Assets8.78%
Miscellaneous
Employees11,800
Outstanding Shares48,030,000
Market Cap$6.24 billion
Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions
What is Charles River Laboratories Intl.'s stock symbol?
Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories Intl.'s stock buyback program work?
Charles River Laboratories Intl. announced that its Board of Directors has authorized a stock repurchase plan on Sunday, June 4th 2017, which authorizes the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Charles River Laboratories Intl.'s earnings last quarter?
Charles River Laboratories Intl. Inc (NYSE:CRL) released its quarterly earnings results on Wednesday, August, 8th. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.46 by $0.16. The medical research company earned $585.30 million during the quarter, compared to analyst estimates of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The firm's revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.29 EPS. View Charles River Laboratories Intl.'s Earnings History.
When is Charles River Laboratories Intl.'s next earnings date?
What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?
Charles River Laboratories Intl. issued an update on its FY18 earnings guidance on Wednesday, August, 8th. The company provided earnings per share (EPS) guidance of $5.85-6.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.84. The company issued revenue guidance of $2.21-2.25 billion (+19-21%), compared to the consensus revenue estimate of $2.21 billion.
What price target have analysts set for CRL?
14 brokerages have issued twelve-month price objectives for Charles River Laboratories Intl.'s stock. Their predictions range from $112.00 to $145.00. On average, they anticipate Charles River Laboratories Intl.'s stock price to reach $128.00 in the next twelve months. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Charles River Laboratories Intl..
What is the consensus analysts' recommendation for Charles River Laboratories Intl.?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..
Who are some of Charles River Laboratories Intl.'s key competitors?
Some companies that are related to Charles River Laboratories Intl. include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY) and Pieris Pharmaceuticals (PIRS).
Who are Charles River Laboratories Intl.'s key executives?
Charles River Laboratories Intl.'s management team includes the folowing people:
- Mr. James C. Foster, Chairman, CEO & Pres (Age 67)
- Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 52)
- Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 57)
- Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 41)
Has Charles River Laboratories Intl. been receiving favorable news coverage?
Media coverage about CRL stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Charles River Laboratories Intl. earned a news impact score of 0.18 on Accern's scale. They also gave news stories about the medical research company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Charles River Laboratories Intl..
Who are Charles River Laboratories Intl.'s major shareholders?
Charles River Laboratories Intl.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.28%), Renaissance Technologies LLC (3.15%), Ariel Investments LLC (2.75%), Wells Fargo & Company MN (2.75%), FMR LLC (2.57%) and FMR LLC (2.56%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..
Which major investors are selling Charles River Laboratories Intl. stock?
CRL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Millennium Management LLC, Aristotle Capital Boston LLC, Russell Investments Group Ltd., Canada Pension Plan Investment Board, Bank of Montreal Can and Ariel Investments LLC. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..
Which major investors are buying Charles River Laboratories Intl. stock?
CRL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Schwab Charles Investment Management Inc., Massachusetts Financial Services Co. MA, Wells Fargo & Company MN, Renaissance Technologies LLC, Advisors Asset Management Inc. and Natixis. Company insiders that have bought Charles River Laboratories Intl. stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories Intl..
How do I buy shares of Charles River Laboratories Intl.?
Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories Intl.'s stock price today?
One share of CRL stock can currently be purchased for approximately $128.89.
How big of a company is Charles River Laboratories Intl.?
Charles River Laboratories Intl. has a market capitalization of $6.24 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories Intl. employs 11,800 workers across the globe.
How can I contact Charles River Laboratories Intl.?
Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]
MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
